Liposomes as immunological adjuvants and delivery systems in the development of tuberculosis vaccine: A review
Asian Pacific Journal of Tropical Medicine
; (12): 7-16, 2022.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-939470
Responsible library:
WPRO
ABSTRACT
Liposomes are phospholipid bilayer vesicles, which are biocompatible, biodegradable and nontoxic vehicles suitable for numerous drug and gene delivery applications. In this review, we discuss the prospect of using liposome technology in the development of a vaccine for tuberculosis. Tuberculosis remains an important health problem that requires the development of an effective vaccine, especially since the only approved vaccine for it continues to be the Bacille Calmette-Geurin (BCG) one developed 100 years ago. This review focuses on the different applications of liposomes toward achieving this goal. Numerous liposomal formulations showing prospect in the research stage and in clinical trials are discussed.
Full text:
Available
Health context:
Sustainable Health Agenda for the Americas
/
Neglected Diseases
Health problem:
Goal 10: Communicable diseases
/
Neglected Diseases
/
Tuberculosis
Database:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Aspects:
Patient-preference
Language:
Chinese
Journal:
Asian Pacific Journal of Tropical Medicine
Year:
2022
Document type:
Article